Levilimab Biosimilar - Research Grade

Human

IL6R

>1mg/ml

IgG1 - kappa

CHO Cells

Tocilizumab Biosimilar - Research Grade (ICH4012), Satralizumab Biosimilar - Research Grade (ICH5106), Sarilumab Biosimilar - Research Grade (ICH5107)

https://www.imgt.org/mAb-DB/

ICH3002

P08887

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of the anti-IL-6 receptor antibody levilimab, produced for research use only. It reproduces the human IgG1/kappa framework and the antigen-binding activity directed against the human interleukin-6 receptor (IL6R), making it a convenient tool for studying IL-6/IL-6R pathway biology and for characterizing receptor-directed antibody activity in the laboratory. Because it is built around the IL6R target rather than manufactured as a clinical product, it is well suited to in-vitro binding and neutralization assays, as an isotype-matched positive/reference control alongside other anti-IL6R reagents, for antibody-engineering and ADC/ADCC method development, and for preclinical bench work where a defined, consistent anti-IL6R IgG1 is needed. It is offered as a low-endotoxin (research-grade <1 EU/mg, ultra-low <0.5 EU/mg options), bulk mg-to-gram research reagent. It is not the clinical drug and is not intended for human or veterinary therapeutic use. Content is provided for ichorbio to review. IL6R (UniProt P08887) is the specific, non-signaling alpha subunit of the interleukin-6 receptor. Interleukin-6 first binds IL6R, and this IL-6/IL6R complex then recruits and dimerizes the signal-transducing beta subunit gp130 (IL6ST), triggering JAK/STAT3 signaling that drives acute-phase responses, immune-cell differentiation, and inflammation. IL6R exists as a membrane-bound form on hepatocytes and leukocytes ("classic" signaling) and as a soluble form (sIL6R) that enables "trans-signaling" on cells lacking membrane IL6R but expressing gp130, broadening the range of responsive cell types. Because dysregulated IL-6 signaling underlies chronic inflammatory and autoimmune conditions, IL6R is a validated point for pathway blockade. Antibodies against IL6R prevent IL-6 engagement, interrupting downstream gp130-dependent signal transduction.

IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, Interleukin-6 receptor subunit alpha

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Levilimab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Levilimab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Levilimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Levilimab that binds IL6R; for research use only.